LncRNA MNX1-AS1: A novel oncogenic propellant in cancers - 20/04/22

Doi : 10.1016/j.biopha.2022.112801

Tengfei Li ^a,^b,^{^{1
Tengfei Li, Shuai Zhou, Yan Yang and Yanyan Xu contributed equally to this work and should be considered co-first authors.}}, Shuai Zhou ^c,^{^{1
Tengfei Li, Shuai Zhou, Yan Yang and Yanyan Xu contributed equally to this work and should be considered co-first authors.}}, Yan Yang ^a,^{^{1
Tengfei Li, Shuai Zhou, Yan Yang and Yanyan Xu contributed equally to this work and should be considered co-first authors.}}, Yanyan Xu ^a,^{^{1
Tengfei Li, Shuai Zhou, Yan Yang and Yanyan Xu contributed equally to this work and should be considered co-first authors.}}, Xin Gong ^a, Yunsheng Cheng ^a, Yong Wang ^a,^⁎
^a Department of General Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230601, China
^b Department of Medicine, The University of Hong Kong, Hong Kong, China
^c The Fourth Department of General Surgery, Anhui No.2 Provincial People’s Hospital, No. 1868 Dangshan Road, North Second Ring, Hefei 230041, Anhui, China

^⁎Corresponding author.

Abstract

To date, recent studies have shown that long non‐coding RNAs (lncRNAs) are key players in gene regulation processes involved in cancer pathogenesis. In general, Motor neuron and pancreas homeobox 1–antisense RNA1 (MNX1-AS1) is highly expressed in all cancers as reported so far and exerts oncogenic effects through different mechanisms. In this review, we comprehensively summarize the detailed mechanisms of potential functions of MNX1-AS1 in different cancer types as well as the latest knowledge highlighting the potential of MNX1-AS1 as a therapeutic target for cancer. Aberrant expression of MNX1-AS1 closely correlates with clinicopathological parameters. such as lymphatic metastasis, tumor size, tumor stage, OS and DFS. Thus, MNX1-AS1 can be used as a diagnostic and prognostic biomarker or even a therapeutic prognostic target. This article reviews its function, molecular mechanism and clinical prognosis in various malignancies.

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : LncRNAs, miRNA, ncRNA, ceRNA, MNX1-AS1, ZEB2-AS1, DDX11–AS1, TUG1, NEAT1, MNX1, GBC, OS, DFS, TFs, EMT, GC, CRC, LC, BC, ESCC, TNBC, STAT, TCGA, CHIP, RBP

Keywords : Long noncoding RNA, MNX1-AS1, Cancer, Oncogenic, Biomarker

Mappa

Introduction

Regulatory mechanisms of MNX1-AS1 in cancer

Function as a ceRNA

Involvement in signaling pathways

Recruiting transcriptional factors (TFs)

Interactions with proteins

Clinical significance of MNX1-AS1 in cancers

Oncogene MNX1-AS1 affects tumor progress and clinical outcomes

MNX1-AS1 function as clinical prognosis/clinicopathological significance in cancers

Conclusions and future prospects

Funding

Author statement

Author contributions

Ethics approval and consent to participate

Consent for publication

Esportazione

Vol 149

Articolo 112801- maggio 2022 Ritorno al numero

Articolo precedente

Adipocytokines: Emerging therapeutic targets for pain management
Shao-Jie Gao, Dai-Qiang Liu, Dan-Yang Li, Jia Sun, Long-Qing Zhang, Jia-Yi Wu, Fan-He Song, Ya-Qun Zhou, Wei Mei

| Articolo seguente

Traumatic brain injury and the development of parkinsonism: Understanding pathophysiology, animal models, and therapeutic targets
Smrithi Padmakumar, Praveen Kulkarni, Craig F. Ferris, Benjamin S. Bleier, Mansoor M. Amiji

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

connettersi o creare un account

LncRNA MNX1-AS1: A novel oncogenic propellant in cancers - 20/04/22

Abstract

Mappa

Citazioni Export

File

Contenuto

Il mio account

Aide & support

Dichiarazione CNIL